AKARI THERAPEUTICS PLC-ADR
AKTX · NASDAQ
Updated at 2026-10-14 09:27:48
- Today's High
- $8.70
- Today’s Low
- $7.90
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $8.70
- Previous Close
- $8.54
- Volume
- 112.4K
- Market Cap
- $15.35M
- P/E Ratio
- --
- EPS
- $0.00
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 401 EAST JACKSON STREET, TAMPA, FL, UNITED STATES, 33602
- Country
- US
- Listing Date
- 2014-01-31
- Fiscal Year End
- December
- Shares Outstanding
- 3.56B
- CIK
- 0001541157
- Website
- www.akaritx.com
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$4.6M
2026-03-31
$15.75M
2025-12-31
$3.22M
2025-09-30
$7.4M
Net Income
2026-06-30
-$4.8M
2026-03-31
-$14.45M
2025-12-31
-$5.29M
2025-09-30
-$6.4M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-2.68
2026-03-31
$-9.72
2025-12-31
--
2025-09-30
$-1.06
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$4.72M
2026-03-31
-$15.25M
2025-12-31
-$4.49M
2025-09-30
-$7.36M
Effective Tax Rate
2026-06-30
--
2026-03-31
5.6%
2025-12-31
-1.63%
2025-09-30
14.52%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $4.6M | $15.75M | $3.22M | $7.4M |
| Net Income | -$4.8M | -$14.45M | -$5.29M | -$6.4M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-2.68 | $-9.72 | -- | $-1.06 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$4.72M | -$15.25M | -$4.49M | -$7.36M |
| Effective Tax Rate | -- | 5.6% | -1.63% | 14.52% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.